UA95939C2 - Thieno-pyridine derivatives as mek inhibitors - Google Patents
Thieno-pyridine derivatives as mek inhibitorsInfo
- Publication number
- UA95939C2 UA95939C2 UAA200809945A UAA200809945A UA95939C2 UA 95939 C2 UA95939 C2 UA 95939C2 UA A200809945 A UAA200809945 A UA A200809945A UA A200809945 A UAA200809945 A UA A200809945A UA 95939 C2 UA95939 C2 UA 95939C2
- Authority
- UA
- Ukraine
- Prior art keywords
- thieno
- pyridine derivatives
- mek inhibitors
- substituted
- mek
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2- position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0601962.4A GB0601962D0 (en) | 2006-01-31 | 2006-01-31 | Therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
UA95939C2 true UA95939C2 (en) | 2011-09-26 |
Family
ID=36100789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200809945A UA95939C2 (en) | 2006-01-31 | 2007-01-30 | Thieno-pyridine derivatives as mek inhibitors |
Country Status (27)
Country | Link |
---|---|
US (3) | US8283359B2 (en) |
EP (1) | EP1981892B1 (en) |
JP (1) | JP5249787B2 (en) |
KR (1) | KR101446919B1 (en) |
CN (1) | CN101379067B (en) |
AU (1) | AU2007211377B2 (en) |
BR (1) | BRPI0708016B1 (en) |
CA (1) | CA2640594C (en) |
CY (1) | CY1115404T1 (en) |
DK (1) | DK1981892T3 (en) |
EA (1) | EA016128B1 (en) |
EC (1) | ECSP088704A (en) |
ES (1) | ES2471970T3 (en) |
GB (1) | GB0601962D0 (en) |
HK (1) | HK1125924A1 (en) |
HR (1) | HRP20140503T1 (en) |
IL (1) | IL192603A (en) |
MY (1) | MY146387A (en) |
NO (1) | NO341064B1 (en) |
NZ (1) | NZ569638A (en) |
PL (1) | PL1981892T3 (en) |
PT (1) | PT1981892E (en) |
RS (1) | RS53342B (en) |
SI (1) | SI1981892T1 (en) |
UA (1) | UA95939C2 (en) |
WO (1) | WO2007088345A1 (en) |
ZA (1) | ZA200807447B (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0601962D0 (en) | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
GB0616214D0 (en) * | 2006-08-15 | 2006-09-27 | Ucb Sa | Therapeutic Agents |
GB0714384D0 (en) | 2007-07-23 | 2007-09-05 | Ucb Pharma Sa | theraputic agents |
CN101945875B (en) * | 2007-12-21 | 2013-04-24 | 健泰科生物技术公司 | Azaindolizines and methods of use |
EP2240494B1 (en) | 2008-01-21 | 2016-03-30 | UCB Biopharma SPRL | Thieno-pyridine derivatives as mek inhibitors |
GB0811304D0 (en) * | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
JP5503930B2 (en) * | 2009-09-18 | 2014-05-28 | 住友化学株式会社 | Method for purifying 3-amino-1-tert-butoxycarbonylpiperidine and citrate salt thereof |
EP2598660B1 (en) | 2010-07-26 | 2017-03-15 | Biomatrica, INC. | Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
EP2598661B1 (en) | 2010-07-26 | 2017-09-27 | Biomatrica, INC. | Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
EP2934572A4 (en) | 2012-12-20 | 2016-11-23 | Biomatrica Inc | Formulations and methods for stabilizing pcr reagents |
EP3327144B1 (en) | 2013-02-25 | 2020-03-25 | Novartis AG | Novel androgen receptor mutation |
EP3008073B1 (en) | 2013-06-11 | 2020-01-01 | Latvian Institute Of Organic Synthesis | Thieno[2,3-b]pyridines as multidrug resistance modulators |
EP3007556B1 (en) | 2013-06-13 | 2020-05-20 | Biomatrica, INC. | Cell stabilization |
EP3942931A1 (en) | 2014-06-10 | 2022-01-26 | Biomatrica, INC. | Stabilization of thrombocytes at ambient temperatures |
CN105384754B (en) * | 2014-09-02 | 2018-04-20 | 上海科州药物研发有限公司 | Heterocycle compound as kinases inhibitor and its preparation method and application |
US20190008859A1 (en) | 2015-08-21 | 2019-01-10 | Acerta Pharma B.V. | Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor |
EP3387411B1 (en) | 2015-12-08 | 2023-05-10 | Biomatrica, INC. | Reduction of erythrocyte sedimentation rate |
MA49141A (en) * | 2017-05-19 | 2020-03-25 | Nflection Therapeutics Inc | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR THE TREATMENT OF SKIN CONDITIONS |
CA3063535A1 (en) | 2017-05-19 | 2018-11-22 | Nflection Therapeutics, Inc. | Fused heteroaromatic-aniline compounds for treatment of dermal disorders |
CN109836434B (en) * | 2017-11-27 | 2020-09-25 | 上海宇耀生物科技有限公司 | Thieno-ring compound and synthesis method and application thereof |
MA55143A (en) * | 2018-11-20 | 2021-09-29 | H Lee Moffitt Cancer Center & Res Institute Inc | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR THE TREATMENT OF SKIN CANCERS |
US11572344B2 (en) | 2018-11-20 | 2023-02-07 | Nflection Therapeutics, Inc. | Cyanoaryl-aniline compounds for treatment of dermal disorders |
CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
CN111138449B (en) * | 2020-01-15 | 2022-11-29 | 四川大学华西医院 | Preparation of dual-targeting ERK1 and ERK5 inhibitors and anti-tumor application thereof |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
GB202205203D0 (en) | 2022-04-08 | 2022-05-25 | UCB Biopharma SRL | Combination with inhibitor |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ501277A (en) | 1997-07-01 | 2002-12-20 | Warner Lambert Co | -2(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
KR20020002370A (en) | 1999-01-13 | 2002-01-09 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | Benzoheterocycles and Their Use as MEK Inhibitors |
WO2000041505A2 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Anthranilic acid derivatives |
CZ303815B6 (en) | 2000-07-19 | 2013-05-15 | Warner-Lambert Company | Oxygenated ester of 4-iodophenylamino benzhydroxamic acid derivative and pharmaceutical composition containing thereof |
EP1482944A4 (en) | 2002-03-13 | 2006-04-19 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
DOP2003000613A (en) | 2002-03-13 | 2003-09-30 | Array Biopharma Inc | DERIVATIVES OF BENCIMIDAZOL N3 RENTED AS MEK INHIBITORS (N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS) |
US20030225273A1 (en) | 2002-03-21 | 2003-12-04 | Michaelides Michael R. | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors |
GB0214268D0 (en) * | 2002-06-20 | 2002-07-31 | Celltech R&D Ltd | Chemical compounds |
CL2003002287A1 (en) * | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPOUNDS DERIVED FROM TIENO [3,2-b] -PIRIDINA-6-CARBONITRILOS AND TIENEO [2,3-b] -PIRIDINA-5-CARBONITRILS, PHARMACEUTICAL COMPOSITION, PROCEDURE OF PREPARATION AND INTERMEDIARY COMPOUNDS, AND THEIR USE IN THE TREATMENT OF CANCER, APOPLEJIA, OSTEOPOROSIS |
AU2003296414A1 (en) * | 2002-12-12 | 2004-07-09 | Pharmacia Corporation | Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors |
KR20060021905A (en) | 2003-06-20 | 2006-03-08 | 셀테크 알앤디 리미티드 | Thienopyridone derivatives as kinase inhibitors |
US20060247269A1 (en) * | 2003-06-20 | 2006-11-02 | Brookings Daniel C | Thienopyridone derivatives as kinase inhibitors |
US20050049276A1 (en) | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
DE602004023207D1 (en) | 2003-07-24 | 2009-10-29 | Warner Lambert Co | BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
WO2005023818A2 (en) * | 2003-09-10 | 2005-03-17 | Gpc Biotech Ag | Heterobicyclic compounds as pharmaceutically active agents |
US7772234B2 (en) | 2003-11-19 | 2010-08-10 | Array Biopharma Inc. | Bicyclic inhibitors of MEK and methods of use thereof |
US7217723B2 (en) | 2004-02-02 | 2007-05-15 | Eisai Co., Ltd. | Heterocyclic compound having oxime group |
CA2620864A1 (en) | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
KR20130058072A (en) | 2005-10-07 | 2013-06-03 | 엑셀리시스, 인코포레이티드 | Azetidines as mek inhibitors for the treatment of proliferative diseases |
GB0601962D0 (en) | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
TW200808769A (en) | 2006-04-18 | 2008-02-16 | Astrazeneca Ab | Therapeutic compounds |
GB0616214D0 (en) | 2006-08-15 | 2006-09-27 | Ucb Sa | Therapeutic Agents |
CA2658725A1 (en) | 2006-08-16 | 2008-02-21 | Exelixis, Inc. | Using pi3k and mek modulators in treatments of cancer |
CN101605540A (en) | 2006-12-14 | 2009-12-16 | 埃克塞利希斯股份有限公司 | Use the method for mek inhibitor |
GB0714384D0 (en) | 2007-07-23 | 2007-09-05 | Ucb Pharma Sa | theraputic agents |
EP2240494B1 (en) | 2008-01-21 | 2016-03-30 | UCB Biopharma SPRL | Thieno-pyridine derivatives as mek inhibitors |
GB0811304D0 (en) | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
-
2006
- 2006-01-31 GB GBGB0601962.4A patent/GB0601962D0/en not_active Ceased
-
2007
- 2007-01-30 EP EP07705076.3A patent/EP1981892B1/en active Active
- 2007-01-30 PL PL07705076T patent/PL1981892T3/en unknown
- 2007-01-30 RS RS20140304A patent/RS53342B/en unknown
- 2007-01-30 BR BRPI0708016-6A patent/BRPI0708016B1/en active IP Right Grant
- 2007-01-30 MY MYPI20082765A patent/MY146387A/en unknown
- 2007-01-30 CN CN2007800040774A patent/CN101379067B/en active Active
- 2007-01-30 NZ NZ569638A patent/NZ569638A/en unknown
- 2007-01-30 CA CA2640594A patent/CA2640594C/en active Active
- 2007-01-30 JP JP2008552878A patent/JP5249787B2/en active Active
- 2007-01-30 ZA ZA200807447A patent/ZA200807447B/en unknown
- 2007-01-30 AU AU2007211377A patent/AU2007211377B2/en active Active
- 2007-01-30 UA UAA200809945A patent/UA95939C2/en unknown
- 2007-01-30 KR KR1020087018972A patent/KR101446919B1/en active IP Right Grant
- 2007-01-30 ES ES07705076.3T patent/ES2471970T3/en active Active
- 2007-01-30 DK DK07705076.3T patent/DK1981892T3/en active
- 2007-01-30 EA EA200801684A patent/EA016128B1/en not_active IP Right Cessation
- 2007-01-30 SI SI200731467T patent/SI1981892T1/en unknown
- 2007-01-30 WO PCT/GB2007/000310 patent/WO2007088345A1/en active Application Filing
- 2007-01-30 PT PT77050763T patent/PT1981892E/en unknown
-
2008
- 2008-07-03 IL IL192603A patent/IL192603A/en active IP Right Grant
- 2008-07-30 US US12/182,931 patent/US8283359B2/en active Active
- 2008-08-28 EC EC2008008704A patent/ECSP088704A/en unknown
- 2008-08-29 NO NO20083739A patent/NO341064B1/en unknown
-
2009
- 2009-04-20 HK HK09103590.9A patent/HK1125924A1/en unknown
-
2012
- 2012-09-05 US US13/604,282 patent/US8394822B2/en active Active
-
2013
- 2013-02-06 US US13/760,788 patent/US8604051B2/en active Active
-
2014
- 2014-06-02 HR HRP20140503TT patent/HRP20140503T1/en unknown
- 2014-06-11 CY CY20141100415T patent/CY1115404T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY146387A (en) | Thieno-pyridine derivatives as mek inhibitors | |
WO2008020206A3 (en) | Fused thiophene derivatives as mek inhibitors | |
NO20060279L (en) | Thienopyridone derivatives as kinase inhibitors | |
RS52824B (en) | ||
AP2011005975A0 (en) | Thieno [2,3-B] pyridine derivatives as viral replication inhibitors. | |
MX344588B (en) | Production of fatty acids and derivatives thereof. | |
ZA201202026B (en) | PYROLO[2,3-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | |
EP3623465A3 (en) | Production of fatty acids and derivatives thereof | |
MX2009009371A (en) | Enhanced production of fatty acid derivatives. | |
WO2009081105A3 (en) | Quinoxaline and quinoline derivatives as kinase inhibitors | |
IL195915A0 (en) | 3-amino -imidazo[1,2-a]pyridine derivatives as sglt inhibitors | |
HK1138758A1 (en) | Pyrazolo (3,4-b) pyridine derivatives as phosphodiesterase inhibitors | |
SI2419428T1 (en) | Imidazo(1,2-a)pyridine derivatives as fgfr kinase inhibitors for use in therapy | |
EP2265616B8 (en) | Furo-and thieno[3,2-c]pyridines | |
IL212716A0 (en) | Thieno [3,2-c] pyridine derivatives as kinase inhibitors for use in the treatment of cancer | |
HK1136557A1 (en) | ||
TW200745137A (en) | Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | |
WO2008013966A3 (en) | Use of 8-quinolinol and its analogs to target cancer stem cells | |
WO2013142253A3 (en) | TREATMENT OF PANCREATIC AND RELATED CANCERS WITH 5-ACYL-6,7-DIHYDROTHIENO[3,2-c]PYRIDINES | |
ZA200709919B (en) | Pyrrol (2,3-B) pyridine derivatives protein kinase inhibitors | |
TH98376B (en) | Pyrolo [2,3-B] pyridine and pyrolo [2,3-B] pyridine [2,3-B] that have been replaced with heteroauryl as inhibitors. Janus Kinesse SE INHIBITORS |